Author

Charles Du Mond

Observed names: C Du Mond, C. Du Mond

Observed institutions: University of Washington, University of Michigan, Fred Hutch Cancer Center, Relypsa (United States)

OpenAlex ID: A5080713383

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1998 · D W Northfelt, B J Dezube, et al. · Journal of Clinical Oncology · 650

Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation

1991 · James M. Goodrich, Motomi Mori, et al. · New England Journal of Medicine · 599

PDF

Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.

1997 · M H White, E J Anaissie, et al. · PubMed · 167

Ganciclovir Treatment of Cytomegalovirus Colitis in AIDS: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study

1993 · Douglas T. Dieterich, Donald P. Kotler, et al. · The Journal of Infectious Diseases · 142

Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval

2017 · Steven M. Brunelli, Charles Du Mond, et al. · American Journal of Kidney Diseases · 92

Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease

2018 · Bertram Pitt, David A. Bushinsky, et al. · ESC Heart Failure · 57

PDF

Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients

2017 · Steven M Brunelli, David M Spiegel, et al. · Nephrology Dialysis Transplantation · 52

Effect of Patiromer on Urinary Ion Excretion in Healthy Adults

2016 · David A. Bushinsky, David M. Spiegel, et al. · Clinical Journal of the American Society of Nephrology · 50

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

2019 · Morie A Gertz, Adam D. Cohen, et al. · Blood · 37

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers

2017 · Lawrence J. Lesko, Elliot Offman, et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 34

Renal Sparing by Amphotericin B Colloidal Dispersion: Clinical Experience in 572 Patients

1999 · M. Gurwith, R. Mamelok, et al. · Chemotherapy · 13

1-year Safety and Efficacy of Patiromer for Hyperkalemia in Heart Failure Patients With Chronic Kidney Disease on Renin-angiotensin-aldosterone System Inhibitors

2015 · Bertram Pitt, David Bushinsky, et al. · Journal of the American College of Cardiology · 10

To028effect of Patiromer on Serum Potassium in Hyperkalemic Patients With Severe Ckd on Raas Inhibitors: Results From Opal-hk and Amethyst-dn

2017 · David Bushinsky, Alain Romero, et al. · Nephrology Dialysis Transplantation · 5

PDF

Mp709comparison of Potassium Values Before and After Patiromer Initiation Among Patients Receiving Chronic Hemodialysis in the United States

2017 · Christopher Rowan, Csaba Kovesdy, et al. · Nephrology Dialysis Transplantation · 1

PDF

1-year safety and efficacy of patiromer for hyperkalemia in heart failure patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors

2015 · Bertram Pitt, David A. Bushinksy, et al. · Heart & Lung · 1

So008effect of the Potassium Binding Polymer Patiromer on Urine Sodium Excretion in Healthy Adults

2016 · David A Bushinsky, David M Spiegel, et al. · Nephrology Dialysis Transplantation

PDF

Opioid-sparing properties of intranasal ketorolac: a pooled analysis of patients experiencing moderate-to-severe acute pain

2010 · L. Bynum, C. Du Mond · Journal of Pain

Author and Subject Index

1999 · B. Dupont, B.E. de Pauw, et al. · Chemotherapy

PDF

Works count: 18

Citation count: 1,910

H-index: 11

I10-index: 12